Aggressive Neuroendocrine Colon and Rectum Tumors

Table of Contents
View All
Table of Contents

If you or a loved one have been diagnosed with an aggressive or high-grade neuroendocrine tumor of the colon or rectum you're probably feeling frightened as well as confused.

Aggressive neuroendocrine tumors are less common than some of the other colon cancers. In addition, they are commonly misdiagnosed and it is important to be your own advocate if you have one of these tumors. What do we know about these cancers, how are they treated, and what is the prognosis?

doctor discussing medical chart with male patient
Hero Images / Getty Images

Overview

Neuroendocrine tumors are tumors which begin in neuroendocrine cells. They can occur in mny ares of the body, including the digestive tract, the lungs, and the brain. In the digestive tract, they may involve the stomach, the pancreas, the small intestine, colon, and rectum.

Neuroendocrine tumors have been increasing, with a fivefold increase noted from 1973 to 2004 and a continued increase since that time. Fortunately, the prognosis for these tumors has improved..

Types of Tumors

Neuroendocrine tumors are first divided into two basic categories based on the aggressiveness of the tumors.

Aggressive vs. Indolent Tumors

It is important to differentiate aggressive and indolent tumors as the optimal treatments and well as prognosis differ considerably:

  • High-grade large cell and small cell neuroendocrine tumors are aggressive. These tumors tend to grow rapidly and invade other tissues
  • Carcinoid tumors of the colon are considered indolent. They tend to be slower growing and less invasive than large cell and small cell neuroendocrine tumors.

Large Cell and Small Cell Tumors

High-grade or aggressive neuroendocrine tumors are divided into a large cell and small cell tumors, which differ based on the appearance of the cells under a microscope. Both types of cancer are considered highly "undifferentiated," which essentially means that the cells appear very primitive relative to normal neuroendocrine cells and behave very aggressively.

In some ways, high-grade neuroendocrine tumors are similar to small cell lung cancer, and often respond to similar treatments, but are less likely to be associated with smoking than small cell lung cancers and are less likely to have metastases to bones and the brain.

Symptoms 

Symptoms of neuroendocrine tumors of the colon may include changes in bowel habits, such as diarrhea, abdominal pain, and both an elevated or decreased blood glucose level. Since these tumors are often found in the later stages, symptoms of advanced cancer such as unintentional weight loss are commonly found.

Ensuring Proper Diagnosis 

Research shows that aggressive neuroendocrine tumors are often initially misdiagnosed as carcinoid tumors. That's an unfortunate mistake since carcinoids grow slowly and seldom spread. If you've been told you have a carcinoid tumor, make sure an experienced pathologist agrees with your diagnosis. Doing so will require that you ask your healthcare provider some key questions:

  • Has a pathologist participated in the final read of my tumor specimen?
  • Is the pathologist experienced in differentiating between aggressive and indolent neuroendocrine tumors?
  • Did the pathologist express any doubts about my diagnosis?

If the answers aren't yes, yes, and no (or really close to that), your medical team has more work to do before providing you with a definitive diagnosis.

Treatment

There are not currently any standard treatments for aggressive neuroendocrine tumors of the colon and rectum. The treatment will, however, depend on the stage of the tumor. If one of these tumors is found in the early stages, a combination of surgery, radiation therapy, immunotherapy, and chemotherapy may be considered.

For advanced-stage high-grade neuroendocrine tumors, chemotherapy is the treatment of choice and can result in longer survival. Chemotherapy regimens are similar to those used to treat small cell lung cancer, usually involving platinum drugs such as Platinol (cisplatin) or Paraplatin (carboplatin).

Research involving genomic profiling of these tumors offers hope that, in the future, targeted therapies may become available to treat the disease.

Prognosis 

Aggressive neuroendocrine tumors are usually diagnosed at more advanced stages, a circumstance that generally results in a poor prognosis.

At the current time, the median survival rate (the length of time after which half of the people have died and half are still living) is six months for colon cancer and 10 months for rectal cancer, with a five-year survival rate of 14.7% (colon) and 16.6% (rectal). In general, a small-cell histology is associated with more aggressive disease and a worse prognosis.

Coping 

Being diagnosed with a high-grade neuroendocrine tumor is not only frightening but can be very confusing as the condition is not very common. The prognosis of the tumor has, unfortunately not changed significantly in recent years, but advances in treatments, such as the advent of targeted therapies and immunotherapy, offers hope that new treatments will be available in the new future.

Talk to your healthcare provider about the option of clinical trials which are evaluating these new treatments. Be your own advocate in your cancer care and ask questions. Ask for help from your loved ones and allow them to help you. In addition, many people find it helpful to reach out to online support communities. Though aggressive neuroendocrine tumors are uncommon and it's unlikely that you have a support group for this in your community, the internet allows you to get in touch with others facing the same thing you are around the world.

5 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. National Institute of Health. Neuroendocrine Tumor.

  2. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342. doi:10.1001/jamaoncol.2017.0589

  3. American Society of Clinical Oncology. Neuroendocrine Tumors: Symptoms and Signs.

  4. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017;19(12):991-1002. doi:10.1016/j.neo.2017.09.002

  5. American Society of Clinical Oncology. Neuroendocrine Tumors: Types of Treatment.

Additional Reading